Multiple system atrophy as emerging template for accelerated drug discovery in α-synucleinopathies

Parkinsonism and Related Disorders

Volumn 20, Issue 8, 2014, Pages 793-799

  Krismer, Florian ^a   Jellinger, Kurt A ^b   Scholz, Sonja W ^c   Seppi, Klaus ^a   Stefanova, Nadia ^a   Antonini, Angelo ^d   Poewe, Werner ^a   Wenning, Gregor K ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INSTITUTE OF CLINICAL NEUROBIOLOGY   (Austria)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d IRCCS SAN CAMILLO HOSPITAL   (Italy)

Author keywords

Drug development; Multiple system atrophy; Parkinson's disease; Synucleinopathies

Indexed keywords

ALPHA SYNUCLEIN; LEVODOPA; LITHIUM; PLACEBO; RASAGILINE;

CLINICAL TRIAL (TOPIC); DEGENERATIVE DISEASE; DRUG RESEARCH; DRUG TARGETING; GENE; GENE DUPLICATION; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; MESENCHYMAL STEM CELL TRANSPLANTATION; NEUROPATHOLOGY; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; SHORT SURVEY; SHY DRAGER SYNDROME; SNCA GENE; DRUG DEVELOPMENT; GENETICS; METABOLISM; MULTIPLE SYSTEM ATROPHY; PATHOLOGY;

ALPHA-SYNUCLEIN; DRUG DISCOVERY; HUMANS; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE;

EID: 84905241925     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2014.05.005     Document Type: Short Survey

References (81)

1. Poulopoulos M., Levy O.A., Alcalay R.N. The neuropathology of genetic Parkinson's disease. Mov Disord 2012, 27:831-842.
2. Lang A.E., Melamed E., Poewe W., Rascol O. Trial designs used to study neuroprotective therapy in Parkinson's disease. Mov Disord 2013, 28:86-95.
3. Hughes A.J., Daniel S.E., Ben Shlomo Y., Lees A.J. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002, 125:861-870.
4. Paul S.M., Mytelka D.S., Dunwiddie C.T., Persinger C.C., Munos B.H., Lindborg S.R., et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010, 9:203-214.
5. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
6. Chartier-Harlin M.C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1167-1169.
7. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
8. Houlden H., Singleton A.B. The genetics and neuropathology of Parkinson's disease. Acta Neuropathol 2012, 124:325-338.
9. Fuchs J., Nilsson C., Kachergus J., Munz M., Larsson E.M., Schule B., et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 2007, 68:916-922.
10. Stefanova N., Tison F., Reindl M., Poewe W., Wenning G.K. Animal models of multiple system atrophy. Trends Neurosci 2005, 28:501-506.
11. Ozawa T., Okuizumi K., Ikeuchi T., Wakabayashi K., Takahashi H., Tsuji S. Analysis of the expression level of alpha-synuclein mRNA using postmortem brain samples from pathologically confirmed cases of multiple system atrophy. Acta Neuropathol 2001, 102:188-190.
12. Simon-Sanchez J., Schulte C., Bras J.M., Sharma M., Gibbs J.R., Berg D., et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009, 41:1308-1312.
13. Scholz S.W., Houlden H., Schulte C., Sharma M., Li A., Berg D., et al. SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol 2009, 65:610-614.
14. Sailer A. First genome-wide association study in multiple system atrophy [abstract]. Mov Disord 2012, 27:1425. Consortium obotMG.
15. Kiely A.P., Asi Y.T., Kara E., Limousin P., Ling H., Lewis P., et al. alpha-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy?. Acta Neuropathol 2013, 125:753-769.
16. McCann H., Stevens C.H., Cartwright H., Halliday G.M. Alpha-synucleinopathy phenotypes. Parkinsonism Relat Disord 2014, 20:S62-S67.
17. Halliday G.M., Holton J.L., Revesz T., Dickson D.W. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 2011, 122:187-204.
18. Pouclet H., Lebouvier T., Coron E., Rouaud T., Flamant M., Toulgoat F., et al. Analysis of colonic alpha-synuclein pathology in multiple system atrophy. Parkinsonism Relat Disord 2012, 18:893-895.
19. Ozawa T. Morphological substrate of autonomic failure and neurohormonal dysfunction in multiple system atrophy: impact on determining phenotype spectrum. Acta Neuropathol 2007, 114:201-211.
20. Armstrong R.A., Cairns N.J., Lantos P.L. Multiple system atrophy (MSA): topographic distribution of the alpha-synuclein-associated pathological changes. Parkinsonism Relat Disord 2006, 12:356-362.
21. Jellinger K.A. More frequent lewy bodies but less frequent Alzheimer-type lesions in multiple system atrophy as compared to age-matched control brains. Acta Neuropathol 2007, 114:299-303.
22. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., Goedert M. Alpha-Synuclein in filamentous inclusions of lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A 1998, 95:6469-6473.
23. Hasegawa M., Fujiwara H., Nonaka T., Wakabayashi K., Takahashi H., Lee V.M., et al. Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. JBiol Chem 2002, 277:49071-49076.
24. Cookson M.R. alpha-Synuclein and neuronal cell death. Mol Neurodegener 2009, 4:9.
25. Schapira A.H. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 2008, 7:97-109.
26. Jellinger K. The role of α-synuclein in neurodegeneration - an update. Transl Neurosci 2012, 3:75-122.
27. Chung C.Y., Koprich J.B., Siddiqi H., Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. JNeurosci 2009, 29:3365-3373.
28. Morfini G., Pigino G., Opalach K., Serulle Y., Moreira J.E., Sugimori M., et al. 1-Methyl-4-phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase C. Proc Natl Acad Sci U S A 2007, 104:2442-2447.
29. Schulz-Schaeffer W.J. The synaptic pathology of alpha-synuclein aggregation in dementia with lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol 2010, 120:131-143.
30. Zaja-Milatovic S., Milatovic D., Schantz A.M., Zhang J., Montine K.S., Samii A., et al. Dendritic degeneration in neostriatal medium spiny neurons in parkinson disease. Neurology 2005, 64:545-547.
31. Wenning G.K., Stefanova N., Jellinger K.A., Poewe W., Schlossmacher M.G. Multiple system atrophy: a primary oligodendrogliopathy. Ann Neurol 2008, 64:239-246.
32. Wakabayashi K., Hayashi S., Yoshimoto M., Kudo H., Takahashi H. NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. Acta Neuropathol 2000, 99:14-20.
33. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24:197-211.
34. Kordower J.H., Chu Y., Hauser R.A., Freeman T.B., Olanow C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008, 14:504-506.
35. Li J.Y., Englund E., Holton J.L., Soulet D., Hagell P., Lees A.J., et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008, 14:501-503.
36. Desplats P., Lee H.J., Bae E.J., Patrick C., Rockenstein E., Crews L., et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 2009, 106:13010-13015.
37. Luk K.C., Kehm V., Carroll J., Zhang B., O'Brien P., Trojanowski J.Q., et al. Pathological alpha-synuclein transmission initiates parkinson-like neurodegeneration in nontransgenic mice. Science 2012, 338:949-953.
38. Miller D.W., Johnson J.M., Solano S.M., Hollingsworth Z.R., Standaert D.G., Young A.B. Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. JNeural Transm 2005, 112:1613-1624.
39. Gao H.M., Kotzbauer P.T., Uryu K., Leight S., Trojanowski J.Q., Lee V.M. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. JNeurosci 2008, 28:7687-7698.
40. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000, 290:985-989.
41. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol 2009, 8:382-397.
42. Fellner L., Jellinger K.A., Wenning G.K., Stefanova N. Glial dysfunction in the pathogenesis of alpha-synucleinopathies: emerging concepts. Acta Neuropathol 2011, 121:675-693.
43. Jecmenica-Lukic M., Poewe W., Tolosa E., Wenning G.K. Premotor signs and symptoms of multiple system atrophy. Lancet Neurol 2012, 11:361-368.
44. Lees A.J., Hardy J., Revesz T. Parkinson's disease. Lancet 2009, 373:2055-2066.
45. Wenning G.K., Geser F., Krismer F., Seppi K., Duerr S., Boesch S., et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 2013, 12:264-274.
46. Wenning G.K., Ebersbach G., Verny M., Chaudhuri K.R., Jellinger K., McKee A., et al. Progression of falls in postmortem-confirmed parkinsonian disorders. Mov Disord 1999, 14:947-950.
47. Petrovic I.N., Ling H., Asi Y., Ahmed Z., Kukkle P.L., Hazrati L.N., et al. Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord 2012, 27:1186-1190.
48. Goldstein D.S. Orthostatic hypotension as an early finding in Parkinson's disease. Clin Auton Res 2006, 16:46-54.
49. Winge K., Fowler C.J. Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord 2006, 21:737-745.
50. Beck R.O., Betts C.D., Fowler C.J. Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. JUrol 1994, 151:1336-1341.
51. Magerkurth C., Schnitzer R., Braune S. Symptoms of autonomic failure in Parkinson's disease: prevalence and impact on daily life. Clin Auton Res 2005, 15:76-82.
52. Gao X., Chen H., Schwarzschild M.A., Glasser D.B., Logroscino G., Rimm E.B., et al. Erectile function and risk of Parkinson's disease. Am J Epidemiol 2007, 166:1446-1450.
53. Mathers S.E., Kempster P.A., Law P.J., Frankel J.P., Bartram C.I., Lees A.J., et al. Anal sphincter dysfunction in Parkinson's disease. Arch Neurol 1989, 46:1061-1064.
54. Gilman S., Wenning G.K., Low P.A., Brooks D.J., Mathias C.J., Trojanowski J.Q., et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008, 71:670-676.
55. Iranzo A., Santamaria J., Rye D.B., Valldeoriola F., Marti M.J., Munoz E., et al. Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD. Neurology 2005, 65:247-252.
56. Claassen D.O., Josephs K.A., Ahlskog J.E., Silber M.H., Tippmann-Peikert M., Boeve B.F. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology 2010, 75:494-499.
57. O'Sullivan S.S., Massey L.A., Williams D.R., Silveira-Moriyama L., Kempster P.A., Holton J.L., et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain 2008, 131:1362-1372.
58. Brown R.G., Lacomblez L., Landwehrmeyer B.G., Bak T., Uttner I., Dubois B., et al. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain 2010, 133:2382-2393.
59. Hely M.A., Morris J.G., Reid W.G., Trafficante R. Sydney multicenter study of parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005, 20:190-199.
60. Doty R.L. Olfactory dysfunction in parkinson disease. Nat Rev Neurol 2012, 8:329-339.
61. Poewe W. The natural history of Parkinson's disease. JNeurol 2006, 253(Suppl.7). VII2-6.
62. Damon-Perriere N., Foubert-Samier A., De Cock V.C., Gerdelat-Mas A., Debs R., Pavy-Le Traon A., et al. Assessment of the scopa-aut questionnaire in multiple system atrophy: relation to UMSARS scores and progression over time. Parkinsonism Relat Disord 2012, 18:612-615.
63. Wild E.J., Fox N.C. Serial volumetric MRI in parkinsonian disorders. Mov Disord 2009, 24:S691-S698.
64. Messina D., Cerasa A., Condino F., Arabia G., Novellino F., Nicoletti G., et al. Patterns of brain atrophy in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. Parkinsonism Relat Disord 2011, 17:172-176.
65. Seppi K. MRI for the differential diagnosis of neurodegenerative parkinsonism in clinical practice. Parkinsonism Relat Disord 2007, 13:S400-S405.
66. Vingerhoets F.J., Snow B.J., Lee C.S., Schulzer M., Mak E., Calne D.B. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 1994, 36:759-764.
67. Marek K., Innis R., van Dyck C., Fussell B., Early M., Eberly S., et al. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001, 57:2089-2094.
68. Nocker M., Seppi K., Donnemiller E., Virgolini I., Wenning G.K., Poewe W., et al. Progression of dopamine transporter decline in patients with the parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]beta-CIT SPECT. Eur J Nucl Med Mol Imaging 2012, 39:1012-1020.
69. Pellecchia M.T., Barone P., Vicidomini C., Mollica C., Salvatore E., Ianniciello M., et al. Progression of striatal and extrastriatal degeneration in multiple system atrophy: a longitudinal diffusion-weighted MR study. Mov Disord 2011, 26:1303-1309.
70. Seppi K., Schocke M.F., Mair K.J., Esterhammer R., Scherfler C., Geser F., et al. Progression of putaminal degeneration in multiple system atrophy: a serial diffusion MR study. NeuroImage 2006, 31:240-245.
71. Reginold W., Lang A.E., Marras C., Heyn C., Alharbi M., Mikulis D.J. Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord 2014, 20:222-225.
72. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on parkinson disease progression. JAMA 2002, 287:1653-1661. Parkinson Study Group.
73. Whone A.L., Watts R.L., Stoessl A.J., Davis M., Reske S., Nahmias C., et al. Slower progression of parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003, 54:93-101.
74. Ahlskog J.E. Slowing parkinson's disease progression: recent dopamine agonist trials. Neurology 2003, 60:381-389.
75. Albin R.L., Frey K.A. Initial agonist treatment of parkinson disease: a critique. Neurology 2003, 60:390-394.
76. Sossi V., Dinelle K., Schulzer M., Mak E., Doudet D.J., de la Fuente-Fernandez R. Levodopa and pramipexole effects on presynaptic dopamine PET markers and estimated dopamine release. Eur J Nucl Med Mol Imaging 2010, 37:2364-2370.
77. Poewe W., Barone P., Giladi N., Gilman S., Low P.A., Sampaio C., et al. Arandomized, placebo-controlled clinical trial to assess the effects of rasagiline in patients with multiple system atrophy of the parkinsonian subtype [abstract]. Mov Disord 2012, 27:1182.
78. Lee P.H., Lee J.E., Kim H.S., Song S.K., Lee H.S., Nam H.S., et al. Arandomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol 2012, 72:32-40.
79. Kikuchi A., Takeda A., Okamura N., Tashiro M., Hasegawa T., Furumoto S., et al. Invivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy. Brain 2010, 133:1772-1778.
80. Osaki Y., Ben-Shlomo Y., Lees A.J., Wenning G.K., Quinn N.P. Avalidation exercise on the new consensus criteria for multiple system atrophy. Mov Disord 2009, 24:2272-2276.
81. Low P.A., Robertson D., Gilman S., Kaufmann H., Singer W., Biaggioni I., et al. Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014, 13:268-275.